Insight into the profibrinolytic activity of heparin: Effects on the activation of plasminogen mediated by urokinase

Blood Coagulation and Fibrinolysis

Volumn 8, Issue 7, 1997, Pages 403-410

  Bertolesi, G E ^a,c   Farias E F ^a   Alonso, D F ^b   Bal De Kier Joffe E ^a   Lauria De Cidre L S ^a   Eijan A M ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^c Instituto de Oncologia Angel H Roffo   (Argentina)

Author keywords

Fibrinolysis; Heparin; Heparinoid; Plasminogen activators; Urokinase

Indexed keywords

GLOBULIN; HEPARAN SULFATE; HEPARIN; HEPARIN DERIVATIVE; PLASMINOGEN; UROKINASE;

ANIMAL EXPERIMENT; ARTICLE; BINDING COMPETITION; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BINDING; FIBRINOLYSIS; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTHROMBIN TIME;

EID: 0030716917     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199710000-00005     Document Type: Article

References (43)

1. Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246: 355-357.
2. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-6505.
3. Casu B. Structure and biological activity of heparin. Adv Carbohydr Chem Biochem 1985; 43: 51-134.
4. Evans DLI, Marshall CJ, Christey PB, Carrell RW. Heparin binding site, conformational change and activation of antithrombin. Biochemistry 1992; 31: 12629-12642.
5. Holmer E, Kurachi K, Söderström G. The molecular weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor XIIa and kallikrein by antithrombin. Biochem J 1981; 193: 395-400.
6. Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583.
7. Lindahl U, Bäckström G, Thunberg L. The anti-thrombin binding sequence in heparin. Identification of an essential 6-O-sulfate group. J Biol Chem 1983; 258: 599-609.
8. Riesenfeld J, Thunberg L, Höök M, Lindahl U. The antithrombin binding sequence of heparin. Location of essential N-sulfate groups. J Biol Chem 1981; 256: 2389-2394.
9. Robbins KC, Summaria L, Hsieh B, Shah R. The peptide chains of human plasmin. Mechanism of activation of human plasminogen. J Biol Chem 1967; 242: 2333-2342.
10. Pâques E-P, Stöhr H-A, Heimburger N. Study on the mechanism of action of heparin and related substances on the fibrinolytic system: relationship between plasminogen activators and heparin. Thromb Res 1986; 42: 797-807.
11. Andrade-Gordon P, Strickland S. Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen. Biochemistry 1986; 25: 4033-4040.
12. Stein PL, Van Zonneveld A-J, Pannekock H, Strickland S. Structural domains of human tissue-type plasminogen activator that confer stimulation by heparin. J Biol Chem 1989; 264: 15441-15444.
13. Andrade-Gordon P, Strickland S. Fractionation of heparin by chromatography on a tissue plasminogen activator-Sepharose column. Proc Natl Acad Sci USA 1990; 87: 1865-1869.
14. Edelberg JM, Conrad EH, Pizzo SV. Heparin oligasaccharides enhanced tissue-type plasminogen activator: a correlation between oligosaccharide length and stimulation of plasminogen activation. Biochemistry 1991; 30: 10999-11003.
15. Markwardt EG, Klöcking HP. Heparin-induced release of plasminogen activator. Haemostasis 1977; 6: 370-374.
16. Vairel EG, Bouty-Boye H, Toulemonde F, Doutremepuich C, Marsh NA, Gaffney PJ. Heparin and low molecular weight fraction enhances thrombolysis and by this pathway excercises a protective effect against thrombosis. Thromb Res 1983; 30: 219-224.
17. Stephens RW, Pöllänen J, Tapiovaara H, Woodrow G, Vaheri A. Stimulation of cell surface plasminogen activation by heparin and related polyionic substances. Semin Thromb Hemost 1991; 17: 201-209.
18. Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis 1988; 2: 73-84.
19. Todd AS. Endothelium and fibrinolysis. Atherosclerosis 1977; 15: 137-140.
20. Saksela O. Radial caseinolysis in agarose: a simple method for detection of plasminogen activator in the presence of inhibitory substances and serum. Ann Biochem 1981; 111: 276-282.
21. Alonso DF, Farias EF, Bal de Kier Joffé E. Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas. Cancer Lett 1993; 70: 181-187.
22. Belfort DA, Hendry IA, Parish CR. Ability of different chemically modified heparins to potentiate the biological activity of heparin-binding growth factor. I: Lack of correlation with growth factor binding. Biochemistry 1992; 31: 6498-6503.
23. Laemmli U. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
24. Alonso DF, Bertolesi GE, Farias EF, Eiján AM, Bal de Kier Joffé E, Lauría de Cidre L. Antimetastatic effects associated with anticoagulant properties of heparin and chemically modified heparin species in a mouse mammary tumor model. Oncology Rep 1996; 3: 219-222.
25. Hauert J, Nicoloso G, Schleuning W, Bachmann F, Shapira M. Plasminogen activators in dextran sulfate-activated euglobulin fractions: a molecular analysis of factor XII- and prekalikrein-dependent fibrinolysis. Blood 1989; 4: 994-999.
26. Granelli-Piperno A, Reich EA. Study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-234.
27. Vasalli JD, Bellin D. Amiloride selectively inhibit the urokinase type plasminogen activator. FEBS Lett 1987; 214: 187-191.
28. Kyhese-Andersen J. Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. J Biochem Biophys Methods 1984; 10: 203-209.
29. Astrup T, Rosa AT. A plasminogen proactivator-activator system in human blood effective in absence of Hageman factor. Thromb Res 1974; 4: 609-613.
30. Vinazzer H, Stemberger A, Haas S, Blümel G. Influence of heparin, of different heparin fractions and of a low molecular weight heparin-like substance on the mechanism of fibrinolysis. Thromb Res 1982; 27: 341-352.
31. Danø K, Andreasen PA, Gr ndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-266.
32. Amiral J, Plassart V, Contant G, Guyader AM. Different method for the determination of tissue plasminogen activator (tPA) and of its inhibitor (PAI). J Clin Lab Inst Reag 1990; 13: 599-610.
33. Chang J-Y. Binding of heparin to human antithrombin III activates selective chemical modification at lysine 236. J Biol Chem 1989; 264: 3111-3115.
34. Kluft C, Trumpi-Kalshoven M, Jie A, Veldhuyzen-Stolk E. Factor XII dependent fibrinolysis: a double function of plasma kalikrein and the occurrence of a previously undescribed factor XII- and kalikrein-dependent plasminogen activity. Thromb Haemost 1979; 41: 756-773.
35. Moskowitz RW, Schwartz HJ, Michel B, Ratnoff OD, Astrup T. Generation of kinin-like agents by chondroitin sulfate, heparin, chitin sulfate and human articular cartilage. Possible pathophysilogic implications. J Lab Clin Med 1970; 76: 790-798.
36. Marsh NA, Born GVR. In vivo and in vitro effects of low molecular weight heparan sulphate on the human fibrinolytic enzyme system. Blood Coag Fibrinol 1991; 2: 453-458.
37. Bertolesi GE, Lauría de Cidre L, Eiján AM. Growth inhibition of murine mammary adenocarcinoma cells by heparin and chemically modified heparins. Tumor Biol 1994; 15: 275-283.
38. Bertolesi GE, Lauría de Cidre L, Sacerdote de Lustig E, Eiján AM. Heparin receptors in two murine mammary adenocarcinomas with different metastatic ability. Relationship with growth inhibition. Cancer Lett 1995; 90: 123-131.
39. Pukac LA, Castellot JJ, Wright TC, Caleb BL, Karnovsky MJ. Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. Cell Regul 1990; 1: 435-443.
40. Au YPT, Kenagy RD, Clowes AW. Heparin selectively inhibits the transcription of tissue-type plasminogen activator in primate arterial smooth muscle cells during mitogenesis. J Biol Chem 1992; 267: 3438-3444.
41. Damon DH, Lobb RR, D'Amore PA, Wagner JA. Heparin potentiates the action of acidic fibroblast growth factor by prolonging its half-life. J Cell Physiol 1989; 138: 221-226.
42. Rosengart T K, Johnson WV, Friesel R, Clark R, Maciag T. Heparin protects heparin-binding growth factor-I from proteolytic inactivation in vitro. Biochem Biophys Res Commun 1988; 152: 432-440.
43. Porta R, Pescador R, Niada R, Diamantini G, Fedeli GF, Mantovani M, et al. Profibrinolytic activities of chemically modified heparins with very low anti-coagulant activities. Thromb Res 1989; 53: 435-445.